HRP20240255T1 - Ketamin pamoat i njegova uporaba - Google Patents
Ketamin pamoat i njegova uporaba Download PDFInfo
- Publication number
- HRP20240255T1 HRP20240255T1 HRP20240255TT HRP20240255T HRP20240255T1 HR P20240255 T1 HRP20240255 T1 HR P20240255T1 HR P20240255T T HRP20240255T T HR P20240255TT HR P20240255 T HRP20240255 T HR P20240255T HR P20240255 T1 HRP20240255 T1 HR P20240255T1
- Authority
- HR
- Croatia
- Prior art keywords
- ketamine
- pamoate salt
- pharmaceutical preparation
- xrpd pattern
- pamoate
- Prior art date
Links
- 229960003299 ketamine Drugs 0.000 title claims 14
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 title claims 12
- 150000003839 salts Chemical class 0.000 claims 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042458 Suicidal ideation Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000005809 status epilepticus Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (12)
1. Pamoatna sol ketamina naznačena time što ima stehiometriju od 2:1 ketamina prema pamoatu.
2. Pamoatna sol ketamina u skladu sa patentnim zahtjevom 1, naznačena time što je:
pamoatna sol R, S-ketamina predstavljena pomoću formule (I) u nastavku:
[image]
pamoatna sol S-ketamina predstavljena pomoću formule (II) u nastavku:
[image]
ili
pamoatna sol R-ketamina predstavljena pomoću formule (III) u nastavku:
[image]
3. Pamoatna sol ketamina u skladu sa patentnim zahtjevom 1, naznačena time što je amorfna.
4. Pamoatna sol ketamina u skladu sa patentnim zahtjevom 1, naznačena time što je kristalna i ima obrazac difrakcije rendgenskih zraka na prahu (XRPD) koji sadrži jednu ili više 2θ vrijednosti ± 0.2 2θ koje su odabrane od 6.0, 10.7, 11.6, 12.0, 13.0, 14.7, 15.0, 19.6, 22.2, 25.2 i 30.3.
5. Pamoatna sol ketamina u skladu sa patentnim zahtjevom 2, naznačena time što je pamoatna sol R, S-ketamina kristalna i ima XRPD obrazac koji je predstavljen pomoću najmanje jednog od sljedećih:
(i) XRPD obrazac koji sadrži jednu ili više 2θ vrijednosti ± 0.2 2θ koje su odabrane od 6.0, 8.6, 10.7, 11.6, 12.0, 13.0, 14.7, 15.0, 15.3, 17.9, 18.6, 19.6, 20.0, 21.1, 21.6, 22.2, 23.3, 24.4, 25.2, 25.9, 26.9, 28.6, 29.7, 30.3, 32.4, 34.0 i 36.6; i
(ii) XRPD obrazac koji je pokazan na SL. 2A.
6. Pamoatna sol ketamina u skladu sa patentnim zahtjevom 2, naznačena time što je pamoatna sol S-ketamina kristalna i ima specifičnu rotaciju
[image]
6. i XRPD obrazac koji je predstavljen pomoću najmanje jednog od sljedećih:
(i) XRPD obrazac koji sadrži jednu ili više 2θ vrijednosti ± 0.2 2θ koje su odabrane od 6.0, 10.8, 11.7, 12.0, 12.6, 13.1, 14.6, 15.1, 18.2, 19.2, 19.7, 20.1, 22.0, 22.8, 23.3, 23.7, 24.1, 24.7, 25.2, 27.3, 30.1, 31.6, 45.4, 56.4 i 75.2; i
(ii) XRPD obrazac koji je pokazan na SL. 2B.
7. Pamoatna sol ketamina u skladu sa patentnim zahtjevom 2, naznačena time što je pamoatna sol R-ketamina kristalna i ima specifičnu rotaciju
[image]
7. i XRPD obrazac koji je predstavljen pomoću najmanje jednog od sljedećih:
(i) XRPD obrazac koji sadrži jednu ili više 2θ vrijednosti ± 0.2 2θ koje su odabrane od 6.0, 10.8, 11.7, 12.0, 12.6, 13.1, 14.6, 15.0, 18.2, 19.3, 19.7, 20.6, 22.0, 22.9, 23.6, 24.1, 24.7, 25.2, 25.9, 27.3, 30.1, 31.6, 45.4, 56.4 i 75.2; i
(ii) XRPD obrazac koji je pokazan na SL. 2C.
8. Pamoatna sol ketamina u skladu sa bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što ima čistoću veću od 95%.
9. Farmaceutski pripravak za uporabu u liječenju bolesti centralnog nervnog sistema (CNS), koji sadrži primjenu subjektu kojem je to potrebno efikasne količine farmaceutskog pripravka, naznačeno time što farmaceutski pripravak sadrži pamoatnu sol ketamina u skladu sa bilo kojim od patentnih zahtjeva 1 do 8 i njen farmaceutski prihvatljiv ekscipijens.
10. Farmaceutski pripravak za uporabu u skladu sa patentnim zahtjevom 9, naznačen time što je bolest CNS odabrana iz grupe koja se sastoji od velikog depresivnog poremećaja (MDD), MDD sa neposrednim rizikom od suicidalnih ideja, depresije rezistentne na terapiju (TRD), bipolarnog poremećaja, opsesivno-kompulzivnog poremećaja, posttraumatskog stresnog poremećaja (PTSD), poremećaja iz spektra autizma, tinitusa, refraktorne kronične migrene, astme, anksioznosti, poremećaja uporabe supstanci, poremećaja uporabe alkohola, poremećaja u ishrani, refraktornog status epilepticus, ishemije mozga, Alzheimerove bolesti, Parkinsonove bolesti, moždanog udara, traumatske povrede mozga, multiple skleroze, i bola.
11. Farmaceutski pripravak za uporabu u anesteziranju subjekta kojem je to potrebno, koji sadrži primjenu subjektu efikasne količine farmaceutskog pripravka, naznačen time što farmaceutski pripravak sadrži pamoatnu sol ketamina u skladu sa bilo kojim od patentnih zahtjeva 1 do 8 i njen farmaceutski prihvatljiv ekscipijens.
12. Farmaceutski pripravak za uporabu u skladu sa bilo kojim od patentnih zahtjeva 9 do 11, naznačen time što liječenje bolesti CNS ili anestezija počinje unutar 24 sata i traje najmanje 10 dana poslije primjene farmaceutskog pripravka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791058P | 2019-01-11 | 2019-01-11 | |
| US201962871763P | 2019-07-09 | 2019-07-09 | |
| PCT/CN2020/071404 WO2020143762A1 (en) | 2019-01-11 | 2020-01-10 | Ketamine pamoate and use thereof |
| EP20739053.5A EP3908570B1 (en) | 2019-01-11 | 2020-01-10 | Ketamine pamoate and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240255T1 true HRP20240255T1 (hr) | 2024-05-24 |
Family
ID=71521952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240255TT HRP20240255T1 (hr) | 2019-01-11 | 2020-01-10 | Ketamin pamoat i njegova uporaba |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11981617B2 (hr) |
| EP (1) | EP3908570B1 (hr) |
| JP (1) | JP7451538B2 (hr) |
| KR (1) | KR20210116517A (hr) |
| CN (1) | CN113423686B (hr) |
| AU (1) | AU2020206826B2 (hr) |
| BR (1) | BR112021013340A2 (hr) |
| CA (1) | CA3118954A1 (hr) |
| CL (1) | CL2021001803A1 (hr) |
| CO (1) | CO2021006884A2 (hr) |
| DK (1) | DK3908570T3 (hr) |
| ES (1) | ES2974259T3 (hr) |
| FI (1) | FI3908570T3 (hr) |
| HR (1) | HRP20240255T1 (hr) |
| LT (1) | LT3908570T (hr) |
| MX (1) | MX2021006029A (hr) |
| PE (1) | PE20211550A1 (hr) |
| PH (1) | PH12021551157A1 (hr) |
| PT (1) | PT3908570T (hr) |
| RS (1) | RS65271B1 (hr) |
| SG (1) | SG11202104792SA (hr) |
| SI (1) | SI3908570T1 (hr) |
| TW (1) | TWI827783B (hr) |
| WO (1) | WO2020143762A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753557A4 (en) | 2018-02-15 | 2021-12-01 | National University Corporation Chiba University | PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| EP4076410A4 (en) * | 2019-12-20 | 2024-02-07 | Alar Pharmaceuticals Inc. | LONG-ACTING INJECTABLE FORMULATIONS OF KETAMINE PAMOATE SALTS |
| US20210322669A1 (en) * | 2020-04-16 | 2021-10-21 | Invictus Health, Inc. | Method for treatment of traumatic brain injuries |
| CN112263572A (zh) * | 2020-11-17 | 2021-01-26 | 厦门大学附属翔安医院 | 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020048610A1 (en) | 2000-01-07 | 2002-04-25 | Cima Michael J. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
| US9421266B2 (en) | 2007-05-22 | 2016-08-23 | Pisgah Laboratories, Inc. | Safety of pseudoephedrine drug products |
| JO2857B1 (en) | 2008-06-16 | 2015-03-15 | سانوفي أفينتس | Vinyl pipers with modified activity of tumor-resistant TNF |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| JP2014196292A (ja) | 2013-03-07 | 2014-10-16 | 大塚製薬株式会社 | 医薬 |
| CN106562952B (zh) * | 2015-10-09 | 2020-06-09 | 江阴安博生物医药有限公司 | 氯胺酮在治疗重性抑郁障碍中的应用 |
| US10793536B2 (en) | 2016-03-29 | 2020-10-06 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Vortioxetine pamoic acid salt and crystal form thereof |
| CA3048485C (en) | 2016-12-26 | 2022-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| AU2019206950B2 (en) * | 2018-01-10 | 2021-07-01 | XWPharma Ltd. | Prodrugs of ketamine, compositions and uses thereof |
-
2020
- 2020-01-10 WO PCT/CN2020/071404 patent/WO2020143762A1/en active Application Filing
- 2020-01-10 CA CA3118954A patent/CA3118954A1/en active Pending
- 2020-01-10 SI SI202030367T patent/SI3908570T1/sl unknown
- 2020-01-10 LT LTEPPCT/CN2020/071404T patent/LT3908570T/lt unknown
- 2020-01-10 CN CN202080007207.5A patent/CN113423686B/zh active Active
- 2020-01-10 ES ES20739053T patent/ES2974259T3/es active Active
- 2020-01-10 PE PE2021000756A patent/PE20211550A1/es unknown
- 2020-01-10 BR BR112021013340-2A patent/BR112021013340A2/pt unknown
- 2020-01-10 KR KR1020217025339A patent/KR20210116517A/ko unknown
- 2020-01-10 DK DK20739053.5T patent/DK3908570T3/da active
- 2020-01-10 SG SG11202104792SA patent/SG11202104792SA/en unknown
- 2020-01-10 FI FIEP20739053.5T patent/FI3908570T3/fi active
- 2020-01-10 EP EP20739053.5A patent/EP3908570B1/en active Active
- 2020-01-10 PT PT207390535T patent/PT3908570T/pt unknown
- 2020-01-10 MX MX2021006029A patent/MX2021006029A/es unknown
- 2020-01-10 TW TW109100921A patent/TWI827783B/zh active
- 2020-01-10 AU AU2020206826A patent/AU2020206826B2/en active Active
- 2020-01-10 HR HRP20240255TT patent/HRP20240255T1/hr unknown
- 2020-01-10 US US17/421,407 patent/US11981617B2/en active Active
- 2020-01-10 RS RS20240215A patent/RS65271B1/sr unknown
- 2020-01-10 JP JP2021540341A patent/JP7451538B2/ja active Active
-
2021
- 2021-05-20 PH PH12021551157A patent/PH12021551157A1/en unknown
- 2021-05-25 CO CONC2021/0006884A patent/CO2021006884A2/es unknown
- 2021-07-07 CL CL2021001803A patent/CL2021001803A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS65271B1 (sr) | 2024-03-29 |
| DK3908570T3 (da) | 2024-02-26 |
| CN113423686A (zh) | 2021-09-21 |
| LT3908570T (lt) | 2024-03-12 |
| BR112021013340A2 (pt) | 2021-09-14 |
| JP7451538B2 (ja) | 2024-03-18 |
| SI3908570T1 (sl) | 2024-04-30 |
| EP3908570A1 (en) | 2021-11-17 |
| ES2974259T3 (es) | 2024-06-26 |
| JP2022518003A (ja) | 2022-03-11 |
| PE20211550A1 (es) | 2021-08-16 |
| TW202042796A (zh) | 2020-12-01 |
| WO2020143762A1 (en) | 2020-07-16 |
| EP3908570B1 (en) | 2023-12-13 |
| SG11202104792SA (en) | 2021-06-29 |
| US20220119338A1 (en) | 2022-04-21 |
| AU2020206826B2 (en) | 2024-05-02 |
| PT3908570T (pt) | 2024-03-15 |
| PH12021551157A1 (en) | 2021-11-03 |
| CL2021001803A1 (es) | 2021-12-24 |
| MX2021006029A (es) | 2021-09-23 |
| CA3118954A1 (en) | 2020-07-16 |
| TWI827783B (zh) | 2024-01-01 |
| US11981617B2 (en) | 2024-05-14 |
| KR20210116517A (ko) | 2021-09-27 |
| AU2020206826A1 (en) | 2021-06-03 |
| FI3908570T3 (fi) | 2024-02-13 |
| CO2021006884A2 (es) | 2021-06-10 |
| EP3908570A4 (en) | 2022-10-19 |
| CN113423686B (zh) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240255T1 (hr) | Ketamin pamoat i njegova uporaba | |
| BR112018000041A2 (pt) | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl | |
| ES2802175T3 (es) | Tieno [3,2-d]pirimidinas, furo[3,2,d]pirimidinas y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones del virus sincitial respiratorio | |
| HRP20180098T1 (hr) | Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja | |
| JP2013545730A5 (hr) | ||
| TWI312679B (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| JP2024009945A5 (hr) | ||
| JP2020536858A5 (hr) | ||
| JP2009510044A5 (hr) | ||
| HRP20211906T1 (hr) | Dalargin za upotrebu u liječenju akutne respiratorne virusne infekcije | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| CN104212236B (zh) | 一种具有提神作用的香型墨水 | |
| HUP0401201A2 (hu) | Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására | |
| JP2015524423A5 (hr) | ||
| CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
| CN111620815B (zh) | 手性氯喹、羟氯喹和其衍生物及其制备方法与用途 | |
| Guiloff et al. | Limb pain in migraine and cluster headache. | |
| AR075626A1 (es) | Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso. | |
| JP2019516756A5 (hr) | ||
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| JP2019529569A5 (hr) | ||
| CN105477075A (zh) | 一种治疗鼻窦炎的中药组合物 | |
| JP2017525776A5 (hr) | ||
| JP2020526575A5 (hr) | ||
| JP2015524460A5 (hr) |